{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:34:39Z","timestamp":1789940079049,"version":"4.0.1"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing<jats:italic>vs<\/jats:italic>. a dosing regimen adjusted by body weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Individual concentration\u2013time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10\u00a0mg) every 8\u00a0weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1\u00a0h post\u2010dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme\u2010linked immunosorbent assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A two compartment model with parallel linear and non\u2010linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (<jats:italic>V<\/jats:italic><jats:sub>1<\/jats:sub>), peripheral volume (<jats:italic>V<\/jats:italic><jats:sub>2<\/jats:sub>), inter\u2010compartmental clearance, maximum elimination capacity (VM) and concentration at half\u2010maximum elimination capacity were 0.135\u00a0l\u00a0day<jats:sup>\u20131<\/jats:sup>, 2.71\u00a0l, 1.98\u00a0l, 0.371\u00a0l\u00a0day<jats:sup>\u20131<\/jats:sup>, 8.03\u00a0\u03bcg\u00a0day<jats:sup>\u20131<\/jats:sup>and 27.7\u00a0ng\u00a0ml<jats:sup>\u20131<\/jats:sup>, respectively. Inter\u2010individual variability (IIV) was included on CL,<jats:italic>V<\/jats:italic><jats:sub>1<\/jats:sub>,<jats:italic>V<\/jats:italic><jats:sub>2<\/jats:sub>and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL,<jats:italic>V<\/jats:italic><jats:sub>1<\/jats:sub>and<jats:italic>V<\/jats:italic><jats:sub>2<\/jats:sub>significantly reduced IIV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk\u00a0:\u00a0benefit.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12850","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T14:32:59Z","timestamp":1448634779000},"page":"688-699","source":"Crossref","is-referenced-by-count":20,"title":["Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain"],"prefix":"10.1111","volume":"81","author":[{"given":"E. Niclas","family":"Jonsson","sequence":"first","affiliation":[{"name":"Pharmetheus AB Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujia","family":"Xie","sequence":"additional","affiliation":[{"name":"Pfizer Ltd. Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott F.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Pfizer Ltd. Sandwich UK and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalin H.","family":"Arends","sequence":"additional","affiliation":[{"name":"Pfizer Inc Groton CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Relieving pain in America: a blueprint for transforming prevention, care, education, and research","author":"Institute of Medicine","year":"2011"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31821b1ac5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2005.12.001"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2009.12.006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0908913"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/0063030-200822060-00002"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1110\/ps.035402.108"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.02.022"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.03.039"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.05.006"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37950"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.03.006"},{"key":"e_1_2_9_14_1","unstructured":"ArendsR LalovicB MarshallS CaiC\u2010H OlsonS. Population pharmacokinetics of an anti\u2010NGF humanized antibody tanezumab in patients with osteoarthritis: Support to adoption of fixed\u2010dose regimen. Presented at American Association of Pharmaceutical Scientists \u2013 2009 National Biotechnology Conference.2009."},{"key":"e_1_2_9_15_1","unstructured":"XieR ArendsR OlsonS MarshallS. Preliminary pharmacokinetic\/pharmacodynamic (PK\/PD) analysis for the effect of tanezumab on overall daily pain score data in adults with moderate\u2010to\u2010severe pain due to osteoarthritis of the knee. Presented at: the 2009 annual meeting of the Population Approach Group in Europe (PAGE); 23\u201326June2009; St Petersburg Russia. [cited 20November2014]. Available fromhttp:\/\/www.page\u2010number.org\/pdf_assets\/7555\u2010PAGE%20Tanezumab%20poster%_2009"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131294"},{"key":"e_1_2_9_17_1","unstructured":"U.S. Department of Health and Human Services U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Population Pharmacokinetics.1999[cited 16September 2013]. Available from GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072137.pdf"},{"key":"e_1_2_9_18_1","unstructured":"EuropeanMedicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Guideline on reporting the results of population pharmacokinetic analyses.2008[cited 16September2013]. Available fromhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003067.pdf"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06870909"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2012.51"},{"key":"e_1_2_9_26_1","first-page":"94","volume-title":"Fc Receptors and the Action of Antibodies","author":"Mariani G","year":"1990"},{"key":"e_1_2_9_27_1","unstructured":"HurstSI ArendsR HugheyDB VergaraG SheltonD LirasJ. Interspecies scaling of tanezumab an anti\u2010NGF antibody and comparison of the projected human pharmacokinetic parameters to single\u2010dose clinical data. Presented at Annual Scientific Meeting of theAmericanAssociation of Pharmaceutical Scientists (AAPS);2009November8\u201312; Los Angeles CA. Available at:http:\/\/abstracts.aaps.org\/published\/(Accessed Dec 18 2014). 2009."},{"key":"e_1_2_9_28_1","first-page":"37","volume-title":"Fundamental Immunology","author":"Frazer JK","year":"1999"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-012-9260-6"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-009-9142-8"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.24.1.601"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0090-9556(24)15106-9","article-title":"Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys","volume":"28","author":"Nguyen CB","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1994.1093"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0022-3565(25)21215-0","article-title":"Tissue distribution and complex formation with IgE of an anti\u2010IgE antibody after intravenous administration in cynomolgus monkeys","volume":"279","author":"Fox JA","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117880"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E13-04-0174"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/11598090-000000000-00000"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02803.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0718-4"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0027-4"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9395-9"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711515105"},{"key":"e_1_2_9_44_1","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann TA","year":"1969","journal-title":"Prog Allergy"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.148"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008329556"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0729"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004272731"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337512"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901510"},{"key":"e_1_2_9_51_1","unstructured":"Pfizer Inc. Tanezumab Arthritis Advisory Committee Briefing Document.2012[cited 1June2015]. Available fromhttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisDrugsAdvisoryCommittee\/UCM295205.pdf"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12850","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12850","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.12850","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T15:42:44Z","timestamp":1748706164000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/bcp.12850"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12850","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]}}}